Clinical Trial Update: Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma [Phase 2]

View source ↗

Summary

Phase II study comparing interleukin-21 to dacarbazine in metastatic or recurrent melanoma has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Interleukin-21 (recombinant IL-21) (interleukin-21)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-07-21